Corbus Pharmaceuticals Holdings Inc.
Rank 18
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
$5.2600
USD
-6.81%
Market cap
$340,067,379
Total volume
$3,779,246
Shares outstanding
64,651,593
Rank 18
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
Markets
| Exchange | Symbol | Volume (24h) | Volume (%) | Price |
|---|---|---|---|---|
|
|
CRBP |
$3,779,246
|
100% |
$5.2600
|
Chart